CSF1R and neoplasm: Table 1 below highlights several drugs currently explored for their role in inhibiting monocyte induction and influencing TAM behavior across various cancer types: BLZ945 and PLX3397, targeting CSF-1R, are crucial in modulating the tumor microenvironment by reducing monocyte recruitment and enhancing T cell infiltration.